B-cell acute lymphoblastic leukemia(B-ALL) ranks first in incidence among newly diagnosed childhood malignancies. Current clinical treatment primarily relies on conventional chemotherapy, which is limited by poor tolerance and suboptimal long-term prognosis. Blinatumomab, a novel immunotherapy drug, targets CD3 and CD19 antigens to activate T-cell-specific killing of leukemia cells. It has demonstrated significant efficacy in relapsed/refractory B-ALL,minimal residual lesion clearance, and bridging hematopoietic stem cell transplantation. However, its clinical application is constrained by adverse reactions such as cytokine release syndrome and neurotoxicity. This review systematically summarized blinatumomab's mechanism of action, clinical application advancements, adverse effects, management strategies, and explored the future research directions, aiming to provide theoretical insights for optimizing precision therapy in B-ALL.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |